Drugs / CLS12311
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06430671 | Jun 2024 → Dec 2025 | relapsing-remitting multiple sclerosis | Cellerys AG | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLS12311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06430671 ↗ |